A Global Study of the PETAL Consortium

Recruiting now

Conditions studied: T-Cell and NK-Cell Neoplasm

In brief

The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize that machine learning can be leveraged to uncover distinct genetic vulnerabilities that underlie treatment response and resistance for patients with TNKL, thus moving towards personalized treatment solutions.

Key facts

Study ID

NCT06067347

Run by

Massachusetts General Hospital

People needed

1200

Starts

2024-01-05

Expected to finish

2028-01-01

Last updated by the study team

2026-04-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Untreated, relapsed, or refractory histologically confirmed mature T-cell or NK-cell neoplasm.
• All subtypes of PTCL are eligible except for T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders.

You may not qualify if…

• Precursor T/NK neoplasms, T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders.
• Adults who are unable to consent, individuals who are not yet adults such as infants, children and teenagers, pregnant women, and prisoners.

Where it is running

• City of Hope — Duarte, California, United States (enrolling)
• University of Colorado — Denver, Colorado, United States (enrolling)
• Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Mayo Clinic — Rochester, Minnesota, United States (enrolling)
• Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
• OhioHealth — Columbus, Ohio, United States (enrolling)
• University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
• University of Virginia — Charlottesville, Virginia, United States (enrolling)
• Royal Adelaide Hospital — Adelaide, South Australia, Australia (enrolling)
• Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia (enrolling)
• Kyoto University — Kyoto, Japan (enrolling)
• University of Cape Town — Cape Town, South Africa, South Africa (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.